183 related articles for article (PubMed ID: 32864702)
1. Pathological nodal disease defines survival outcomes in patients with lung cancer with tumour major pathological response following neoadjuvant chemotherapy.
Corsini EM; Weissferdt A; Pataer A; Zhou N; Antonoff MB; Hofstetter WL; Mehran RJ; Rajaram R; Rice DC; Roth JA; Vaporciyan AA; Walsh GL; Cascone T; Heymach JV; Swisher SG; Sepesi B
Eur J Cardiothorac Surg; 2021 Jan; 59(1):100-108. PubMed ID: 32864702
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of Pathologic Response in Lymph Nodes of Patients With Lung Cancer Receiving Neoadjuvant Chemotherapy.
Pataer A; Weissferdt A; Vaporciyan AA; Correa AM; Sepesi B; Wistuba II; Heymach JV; Cascone T; Swisher SG
J Thorac Oncol; 2021 Aug; 16(8):1289-1297. PubMed ID: 33857666
[TBL] [Abstract][Full Text] [Related]
3. Optimal adjuvant therapy in clinically N2 non-small cell lung cancer patients undergoing neoadjuvant chemotherapy and surgery: The importance of pathological response and lymph node ratio.
Shinde A; Horne ZD; Li R; Glaser S; Massarelli E; Koczywas M; Erhunmwunsee L; Reckamp KL; Weksler B; Salgia R; Beriwal S; Amini A
Lung Cancer; 2019 Jul; 133():136-143. PubMed ID: 31200820
[TBL] [Abstract][Full Text] [Related]
4. Real-World Effectiveness and Prognostic Factors Analysis of Stages I-III Non-Small Cell Lung Cancer Following Neoadjuvant Chemo-Immunotherapy or Neoadjuvant Chemotherapy.
Liu Z; Gao Z; Zhang M; Wang X; Gong J; Jiang S; Zhang Z
Ann Thorac Cardiovasc Surg; 2022 Apr; 28(2):111-120. PubMed ID: 34776459
[TBL] [Abstract][Full Text] [Related]
5. Agreement on Major Pathological Response in NSCLC Patients Receiving Neoadjuvant Chemotherapy.
Weissferdt A; Pataer A; Vaporciyan AA; Correa AM; Sepesi B; Moran CA; Wistuba II; Roth JA; Shewale JB; Heymach JV; Kalhor N; Cascone T; Hofstetter WL; Lee JJ; Swisher SG
Clin Lung Cancer; 2020 Jul; 21(4):341-348. PubMed ID: 32279936
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of neoadjuvant immunochemotherapy and survival surrogate analysis of neoadjuvant treatment in IB-IIIB lung squamous cell carcinoma.
Liu J; Zhu L; Tang M; Huang X; Gu C; He C; Lv X; Hu J
Sci Rep; 2024 Mar; 14(1):5523. PubMed ID: 38448498
[TBL] [Abstract][Full Text] [Related]
7. Does major pathological response after neoadjuvant Immunotherapy in resectable nonsmall-cell lung cancers predict prognosis? A systematic review and meta-analysis.
Chen Y; Qin J; Wu Y; Lin Q; Wang J; Zhang W; Liang F; Hui Z; Zhao M; Wang J
Int J Surg; 2023 Sep; 109(9):2794-2807. PubMed ID: 37247009
[TBL] [Abstract][Full Text] [Related]
8. Comparison of different criteria for estimating major pathological response in resectable non-small cell lung cancer treated with neoadjuvant chemoimmunotherapy.
Sun W; Liu X; Wang C; Jiang Y; Lin D
Ann Diagn Pathol; 2024 Apr; 69():152268. PubMed ID: 38301396
[TBL] [Abstract][Full Text] [Related]
9. Neo-adjuvant chemotherapy plus immunotherapy in resectable N1/N2 NSCLC.
Du C; Chen Y; Zhou Y; Zheng D; Zhao J; Tang J; Wu Y; Tu Z
BMC Cancer; 2023 Dec; 23(1):1260. PubMed ID: 38129808
[TBL] [Abstract][Full Text] [Related]
10. [Pathological assessment of non-small cell lung cancer resection specimens after neoadjuvant therapy].
Huang Y; Zhang LP; Hou LK; Dong ZW; Zhang W; Wu W; Wu CY
Zhonghua Bing Li Xue Za Zhi; 2021 Jul; 50(7):773-778. PubMed ID: 34405613
[No Abstract] [Full Text] [Related]
11. Response of primary tumor and lymph node in non-small cell lung cancer after neoadjuvant immunotherapy: a pooled analysis.
Zhai WY; Zhao ZR; Chen S; Yu H; Lin YB; Wang YZ; Long H
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36109085
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of pathological node status after neoadjuvant radiotherapy for rectal cancer.
Duchalais E; Glyn Mullaney T; Spears GM; Kelley SR; Mathis K; Harmsen WS; Larson DW
Br J Surg; 2018 Oct; 105(11):1501-1509. PubMed ID: 29663352
[TBL] [Abstract][Full Text] [Related]
13. The impact of driver mutation on the treatment outcome of early-stage lung cancer patients receiving neoadjuvant immunotherapy and chemotherapy.
Su PL; Chen JY; Chu CY; Chen YL; Chen WL; Lin KY; Ho CL; Tsai JS; Yang SC; Chen CW; Wu YL; Tseng YL; Chang CC; Yen YT; Lin CY; Lin CC; Su WC
Sci Rep; 2022 Feb; 12(1):3319. PubMed ID: 35228655
[TBL] [Abstract][Full Text] [Related]
14. Different pathological response and histological features following neoadjuvant chemotherapy or chemo-immunotherapy in resected non-small cell lung cancer.
Alì G; Poma AM; Di Stefano I; Zirafa CC; Lenzini A; Martinelli G; Romano G; Chella A; Baldini E; Melfi F; Fontanini G
Front Oncol; 2023; 13():1115156. PubMed ID: 36845706
[TBL] [Abstract][Full Text] [Related]
15. Is major pathologic response sufficient to predict survival in resectable nonsmall-cell lung cancer patients receiving neoadjuvant chemotherapy?
Cai JS; Li S; Yan SM; Yang J; Yang MZ; Xie CL; Li JB; Feng YF; Yang HX; Hou X
Thorac Cancer; 2021 May; 12(9):1336-1346. PubMed ID: 33751832
[TBL] [Abstract][Full Text] [Related]
16. Number of negative lymph nodes as a prognostic factor for ypN0-N1 breast cancer patients undergoing neoadjuvant chemotherapy.
Xin F; Yu Y; Yang ZJ; Hou LK; Mao JF; Xia L; Wang X; Cao XC
Tumour Biol; 2016 Jun; 37(6):8445-54. PubMed ID: 26733172
[TBL] [Abstract][Full Text] [Related]
17. Postmastectomy Radiation Therapy Based on Pathologic Nodal Status in Clinical Node-Positive Stage II to III Breast Cancer Treated with Neoadjuvant Chemotherapy.
Huang Z; Zhu L; Huang XB; Tang Y; Rong QL; Shi M; Wang WH; Tie J; Shen LF; Chen JY; Zhang J; Wu HF; Cheng J; Liu M; Tan YT; Ma CY; Wang SL; Li YX
Int J Radiat Oncol Biol Phys; 2020 Nov; 108(4):1030-1039. PubMed ID: 32585337
[TBL] [Abstract][Full Text] [Related]
18. A prognostic score for non-small cell lung cancer resected after neoadjuvant therapy in comparison with the tumor-node-metastases classification and major pathological response.
Zens P; Bello C; Scherz A; Koenigsdorf J; Pöllinger A; Schmid RA; Ochsenbein A; Neppl C; Langer R; Berezowska S
Mod Pathol; 2021 Jul; 34(7):1333-1344. PubMed ID: 33714982
[TBL] [Abstract][Full Text] [Related]
19. Surgical multimodality treatment for baseline resectable stage IIIA-N2 non-small cell lung cancer. Degree of mediastinal lymph node involvement and impact on survival.
Decaluwé H; De Leyn P; Vansteenkiste J; Dooms C; Van Raemdonck D; Nafteux P; Coosemans W; Lerut T
Eur J Cardiothorac Surg; 2009 Sep; 36(3):433-9. PubMed ID: 19502079
[TBL] [Abstract][Full Text] [Related]
20. Outcomes after neoadjuvant or adjuvant chemotherapy for cT2-4N0-1 non-small cell lung cancer: A propensity-matched analysis.
Brandt WS; Yan W; Zhou J; Tan KS; Montecalvo J; Park BJ; Adusumilli PS; Huang J; Bott MJ; Rusch VW; Molena D; Travis WD; Kris MG; Chaft JE; Jones DR
J Thorac Cardiovasc Surg; 2019 Feb; 157(2):743-753.e3. PubMed ID: 30415902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
